



TheTrocar Issue 3 Volume 3 / Page 1-21

ISSN: 2736-5530

Adhesions: The Underestimated partner in Surgery: has there been progress in understanding adhesion formation and treatment over the last 30 years (ISGE Recommendation for prevention)

Author:

Bruno J van Herendael<sup>, 1</sup> Daniel Kruschinski<sup>2</sup>

- Affiliation:
- <sup>1</sup> Ziekenhuis Netwerk Antwerpen ZNA Stuivenberg, Antwerp Belgium Università dell'Insubria Varese Italy, ISGE Adhesion Taskforce
- <sup>2</sup> Kruschinski Medical Center, Frankfurt, Germany, ISGE Adhesion Taskforce

### Abstract

Manipulating tissues during surgical interventions causes adhesions. Some tissues and some patients are more prone to form adhesions. When cross linked fibrin is not broken down by the activation of plasminogen to plasmin there remains a fibrin clot causing the adhesion (Tab 1). The incidence of adhesions in open surgery is estimated at an average of 85% in literature. Readmission due to Adhesion Related Disease (ARD) (1) is evaluated at 5% - 10%. Laparoscopy is comparable to laparotomy. Gynaecological surgery patients are seen back by the gynaecologist only in 52% of cases, 26% is seen in general surgery and 14% in urology. Surgery of the ovaries is most at risk (48,1%) followed by fallopian tube surgery (41,2%), uterine surgery (32,1%). Endometriosis surgery has an adhesion incidence of 82% followed by tubal surgery and adhesiolysis 76%, ovarian surgery 75% and myomectomy 68%. Recent investigations have suggested that good surgical technique combined with adhesion barriers does reduce the incidence of adhesions. In laparoscopy and laparotomy meticulous surgical technique is very important. All residual blood has to be rinsed off, preferably with Ringer's lactate combined with the appropriated amount of heparin, diluted and aspirated this after meticulous haemostasis. When possible monopolar and bipolar energies should be replaced by ultrasound or laser (CO2 laser) energy. Using floatation barriers seems not to have an influence on adhesion formation. Gel barriers have a significant effect on adhesion formation as documented by second look laparoscopies. Sheets do prevent adhesions. Using NSAID and corticosteroids in preventing postoperative pain as to help early ambulation after surgery are mainstay in surgery and should be endorsed in the policies to prevent adhesions.

Keywords: Adhesion, prevention, recommendation, hysteroscopy, laparoscopy.

### Introduction

Adhesions and its synonym synechiae (Greek for continuation) are constituted of fibrous band between organs and are one of the underestimated problems complicating the postoperative phase of surgery (Fig 1). Liakakos et al found adhesions to be present in more than 90% of patients after open abdominal surgery and in 55% - 100% of women after pelvic surgery.




Fig 1: The classical image of Intra Uterine adhesions (synechiae) at hysterosalpingography.

The trauma inflicted to the peritoneum starts the process leading to adhesion formation (2) (Fig 2 a-b). In a large study Ellis et al on 29.790 patients, found that 35% of the patients had to be readmitted, twice on average, to the hospital after open abdominal or pelvic surgery due to Adhesion Related Disease (ARD) (1). More than 22% of readmissions did occur within the first year after the initial surgery. The Surgical and

Clinical Adhesion Research study (SCAR) stated that the readmission rate over a period of ten years was 5% for open surgical procedures in gynaecology (3). 40% of the patients with ADR have been readmitted two to even five times. The overall number does suggest that a great number of adhesions do not cause clinical symptoms.





Fig. 2 Classical appearance of post operative adhesions, due to peritoneal damage by previous laparoscopic fertility surgery, at second look laparoscopy



Tab 1 The Coagulation cascade in a nutshell

Intra Uterine Adhesions (IUA) are strings of fibrous tissue connecting opposite walls of the uterine cavity. IUA are found after control hysteroscopy in 31,3% after myomectomy, 6,7% after septectomy and 3,6% after polypectomy (4) There is a conundrum in denominations Asherman's syndrome (Joseph Asherman 1889 -1968) (5). He does refer first to a complete occlusion and stenosis of the cervical os, with as consequence amenorrhea but with atrophic endometrium in the cavity whilst the second syndrome is IUA characterized by painful, reduced menses and secondary infertility. Both syndromes are described after trauma in the uterine cavity under influence of pregnancy hormones. In both syndromes there is a dysfunctional endometrium more pronounced in the first syndrome (Mark Hans Emmanuel, personal communication 2021) The time to

complete intrauterine wound healing is patient dependent and depends on the type of surgery. Full postoperative, healing of the uterine cavity was achieved after hysteroscopic polypectomy in 86% (23/37 women), adhesiolysis in 67% (30/45 women), metroplasty 19% (3/16 women) and myomectomy 18% (12/65 women p<0.05). Metroplasty seems to cause more de novo adhesions 88% (3/16 women) and adhesiolysis 76% (33/45 women) as compared to myomectomy at 40% (26/65 women) or polypectomy at 0% (0/37 women). Overall women with de novo IUA did have difficulties in achieving complete endometrial integrity compared to women with no de novo adhesions 31% (23/74 women) versus 61% (54/989 women) P=0.0003. Yang et al conclude that complete healing is achieved in a range from one to three

months following polypectomy and myomectomy (6).

ISGE suggests to use these data to discuss the IUA problem with the patients undergoing hysteroscopic surgery. (Recommendation II-1/A)

# **1.** Clinical significance of post-operative adhesions

## A) Laparoscopy

The complications will depend on the organs afflicted by the adhesions meaning the location of the adhesions in most cases these will cause chronic pelvic pain, bowel obstruction and infertility (2 - 3)

The complexity of abdominal entry in an ARD abdomen adds significant risks to subsequent surgical reinterventions (7-8)

### B) Hysteroscopy

IUA are symptomatic through menstrual abnormalities (amenorrhoea, hypo-menorrhea, Irregular bleeding). In patients taking oral contraception and/or hormonal therapy these symptoms can be masked. The latter are also masking possible pelvic pain and dysmenorrhea. Reproductive outcome is poor the prevalence is estimated at 43% (922/2151 women) (9). Recurrent miscarriages occur in 5% - 39% of women with IUA (10). An unexpected but very serious problem are the obstetrical complications like placenta accreta/increta, risk of preterm delivery, peri partum hysterectomy due to uterine rupture (11).

# 2. Pathophysiology

### A) Hysteroscopy

Interference with the endometrial lining both by blind procedures like tissue sampling and or curettage, especially post abortion or postpartum (90%) (12) and hysteroscopic procedures can cause IUA. Genital tuberculosis does create IUA but the etiologic importance in the creation of IUA by other forms of endometrial infections is to be proven. The mechanism of restoration of the endometrium are still poorly understood (13).

B) Laparoscopy – Laparotomy – Gasless laparoscopy

I. Classical Model: local phenomenon between opposing lesions

Damage to peritoneal surfaces induces a response starting with an acute inflammatory reaction, and a process involving mesothelial cells, macrophages, exudate with cytokines and coagulation factors, neutrophils and leukocytes (14).

Within hours a peritoneal defect (i.e., caused by a trauma during surgery) is covered with macrophages and mesothelial cells (15). In the circumstances that mesothelial cells are able to cover the lesions fibrinolysis will start and after a few days this will result in re-epithelialization and a smooth surface without IUA. When fibroblast do invade the fibrin clot these will start to grow and proliferate and start to form IUA.

II. Adapted model: the role of the peritoneal cavity (16).

Free floating mesothelial cells are present at all times and their number increases twelve times within in two to five days after injury (17). When extensive lavage is performed at the time of surgery a substantial number of these cells are removed slowing down the natural healing (18). CO2 gas is used to distend the abdominal cavity in laparoscopy this does interrupt homeostasis the same with room air in laparotomy and gasless laparoscopy influencing the mesothelial cells (Tab 2). The direct relation between CO2 insufflation, acidification of the peritoneum and decreased immunoprotection might thus result in an altered adhesion formation (19) (Fig. 3–4). Identified so far is hypoxia of the mesothelial cells due to CO2 pneumoperitoneum. Desiccation of cells, by CO2 pneumoperitoneum manipulation, and tissue have been demonstrated to increase adhesions and this increase is time- and pressure-dependent (20-21).





Fig 3 Scanning electron microscopy of the simple squamous epithelium at 37° Celcius and relative humidity of 95%. Visible are the free floating mesothelial cells (dark entities) (Douglas E Ott)

In gasless laparoscopy care has to be taken not to compromise the anterior peritoneum by pressure of the lift system (22).



Fig. 4 Scanning electron microscopy of the peritoneal damage caused by CO2 flow at 10 lit/min direct exposure. The 60 🖸 protective peritoneal fluid film has been blown away and the relative humidity has been reduced together with the reduction in temperature. The combination of these factors does cause the monolayer of squamous cells to dry out. (Douglas E. Ott)



Tab 2 The appearance of the peritoneum, squamous cell layer, loose connective tissue and mesothelium under different circumstances. Courtesy of Douglas E. Ott Mercer University

# 3. Prevention of adhesions in hysteroscopy

# A) IUCD

In the literature there is no evidence that IUCD prevents IUA formation. The physical barrier of

the IUCD is not proven as the uterine cavity is a virtual cavity and hence separation of layers is only present at the specific position of the IUCD. This means that small T shaped IUCD's have little to no impact. The IUCD should be very large in surface (23). The other effect of the IUCD is that, as a foreign body, it genders an inflammatory response in the endometrium responsible for a negative effect on the recolonization by the endometrium at the impaired surface (24). The progesterone IUCD's suppress the endometrium and are therefore not to be used. The blind introduction of an IUCD after a major adhesiolysis, hysteroscopic procedure, septectomy or myomectomy represents a major risk of infection and perforation (25-26).

The only small RCT does not show difference between the use of only an IUCD and hormonal therapy or a hormonal therapy alone (27).

ISGE recommendation: there is no evidence that IUCD's do reduce IUA formation. Stage 1: A

### B) Barriers

The effectiveness of barriers, hyaluronic acid gel oxide-sodium and polyethylene carboxymethylcellulose gel, has been assessed by five randomized studies and these have been reviewed in several meta-analyses (28,29,30,31,32,33). There is no evidence for an effect favoring the use of any barrier gel following operative hysteroscopy for the key outcomes live birth or clinical pregnancy (RR 3.0, 95% CI 0.35 to 26, P=0.32, 1 study, 30 women, very low-quality evidence). The use of any gel following operative hysteroscopy decreases the incidence of de novo adhesions at second-look hysteroscopy at 1 to 3 months (RR 0.65, 95% CI 0.45 to 0.93, P=0.02, 5 studies, 372 women, very low-quality evidence). After using any gel following operative hysteroscopy there are more AFS 1988 stage I (mild) adhesions (RR 2.81, 95% CI 1.13 to 7.01, P=0.03, 4 studies, 79 women) and less stage II (moderate) adhesions (RR 0.26, 0.09 to 0.80, P=0.02, 3 studies, 58 women) or stage III (severe) adhesions (RR 0.46, 95% CI 0.03 to 7.21, P=0.58, 3 studies, 58 women) (all very low-quality evidence).

ISGE recommendation: Gynaecologist can use gel barriers as these tend to reduce de novo adhesion formation as the one formed are less moderate to severe and more mild adhesions (very low-quality evidence). Gynaecologist should council their patients that there is no evidence for better pregnancy rates or higher birth rates following the use of barriers in operative hysteroscopy Evidence and strength of recommendation I: C.

# C) Medical

Randomized studies to not point at any evidence that estrogens do prevent IUA.

Since its first use in 1964 several regimens have been proposed to promote the reepithelialization of the endometrium after adhesiolysis (34).

No data exists on the ideal dose and length of the therapy. Preoperative estrogen therapy has been suggested to optimize the endometrial growth before the surgical intervention; however, evidence on its effectiveness is lacking. Moreover, the possible adverse effects of hormonal therapy (nausea, thromboembolic disease) should be taken into account when considering its use (35).

ISGE recommendation: Gynaecologists should council their patients that the use of estrogen therapy after hysteroscopic surgery lacks

scientific evidence and could gender side effects Grade II-1: C.

There is no significant evidence from any published study to recommend the use of steroids (such as dexamethasone, hydrocortisone, and prednisolone) in humans, and several side effects still have to be ascertained (36,37).

ISGE recommendation: Gynaecologists are advised to council their patients that the use of steroids cannot be recommended to avoid adhesion formation and could have side effects. Grade II-2: C.

Some case reports describe the use of other medication (aspirin, sildenafil citrate, and nitroglycerin) to promote the perfusion of the endometrium. At present no evidence exists on its efficacy and therefore its use cannot be sustained.

### 4. Surgical technique and equipment

Cold scissors: Here there are several advantages as it remains the most accessible means to deal with adhesions, further the surgeon has a direct view on the surface to treat she/he can avoid destruction of the surrounding endometrium. The five French channel allows for sturdy instruments and the small barrel hysteroscope (3.8 mm median) allows for assessing the uterine cavity without cervical dilatation. The latter allows for treatment of IUA without anaesthesia or sedation in an office setting (See & Treat).

Uni-polar electrical energy implements that the electrons released by the active electrode on the tissues have to travel through the tissues to the

neutral, passive electrode hence causing collateral damage up to 0.6 mm in depth as a median and therefore does lengthen the time period to a restitutio ad integrum of the endometrial lining. Anionic distention medium is must with possible distention fluid а complications. The instruments are of 27 to 25 French outer diameters necessitating a cervical dilatation from 10 – 8 Hegar respectively hence requesting general anaesthesia. Today bivalent uni-bipolar resectoscopes of 15 French are available, not in need of cervical dilatation, but the uni-polar current is felt as painful and irritating by the patients. Here general anaesthesia is still recommended.

Bi-polar energy: the current remains the same monopolar electrical current but now traveling from the active towards the passive or recuperating pole integrated into the same instrument at some 6-8 mm of distance in the 27 French resectoscopes. In the 15 French resectoscopes the distance between the poles is reduced as is the wattage of the current. The electrical current does travel only to the tissues to be operated under direct view. This results in less in-depth destruction of the tissues treated and the surrounding ones. For the large resectoscopes there is still need for dilatation. When bipolar needles of 5 French are used the surgeon can use small barrel diagnostic scope with an outer diameter of 3.8 mm on average. Here cervical dilatation is not necessary and as the passage of the electrical current affects only the tissues treated. The patient is less uncomfortable so office procedures without anaesthesia can be performed.

Laser Light: The only available lasers are the Nd-YAG and Diode laser systems where heat is diffused into the tissues causing thermal damage up to one cm in depth. The fibers are very fragile and expensive to replace. It can be used through small barrel scopes and can therefore be used without anesthesia or sedation. (38).

Mechanical Energy by morcellation: These instruments do not need electrical energy hence the influence on the surrounding tissues is nonexistent. This allows for quicker regeneration of the endometrial lining in polypectomy and removal of retained products of conception. (39,40).

The first generation of morcellators with an outer diameter of 26 French did necessitate general anaesthesia whereas the newer generation with an outer diameter of 19 French can be used without anaesthesia in selected, multiparous, patients for in office procedures.

# 5. Prevention of adhesions in laparoscopy laparotomy and gasless laparoscopy

- A) Technical Surgical Aspects
- 1. Surgical manipulation

Preventing adhesions implicates the use of a meticulous surgical technique.

The aim is to adjust the technique to minimize the trauma to the different structures and above all to the peritoneum, to minimize the risk of infection, to achieve the best optimal haemostasis and to avoid contamination with foreign materials such as glove powder (41,42)

The Halstedian principles of gentle tissue handling and meticulous haemostasis prevent the presence of free blood and ischemic tissues (43). Laparoscopic approach is generally preferred over laparotomy until now however there is no evidence in randomized control trials concerning the formation of adhesions.

### 2. Blood

There is a lack on randomized control trial concerning the importance of blood in the abdominal cavity and adhesion formation. Animal studies however indicate that blood left in the abdominal cavity at surgery is a factor inducing adhesion formation (44). The abdomen should be cleaned with Ringers lactate at the end of the surgery. The blood is easier aspirated if heparin (5.000IU/lit) is added to the Ringers lactate as clot formation is reduced. When there are no peritoneal injuries in animals, small clots do not enhance adhesion formation whilst large clots do (45).)

ISGE recommendation: There is good evidence, in well-designed case-control studies in animals, that rising blood out of the abdomen decreases the formation of adhesions. Grade II-2: A

3. Meshes and Suture material

There are no randomized trials comparing neither meshes nor threads to the formation of adhesions in the human. Leaving a mesh exposed to the abdominal cavity (not covered by peritoneum) will result in an increased risk of adherence to the mesh, with the risk of bowel obstruction. This is also true for exposed barbed sutures (46). The presence of suture material and tightening the sutures to the point of ischemia promotes adhesion formation (47).

ISGE recommendation: gynaecologists should cover all meshes and barbed sutures. The use monofilament resorbable sutures is recommended. Grade II-1: B.

4. Equipment

Ultrasonic and laser energy can be used to minimize tissue damage. Uni-polar energy does most likely cause more tissue damage due to the passage through the tissues on the way to the return electrode.

#### B Conditioning the peritoneal environment

The CO2 gas used to insufflate and to maintain the pneumoperitoneum affects the whole abdominal cavity. There is evidence from small trials in human that switching to a mixture of carbon dioxide with 10% nitrous oxide and 4% oxygen can decrease adhesion (48). A trial study on 44 women who did undergo surgery for resection of endometriosis laparoscopic demonstrated a significant reduction in adhesion formation (P<0.0005) however the patients in the study group did also receive dexamethasone, a rising with heparin was performed and the humidity and the temperature of the abdomen were also monitored (49).

### C) Local products

1. Floatation barriers (Ringer's lactate, Saline, Hartman's solution)

Meta–analysis of clinical trial demonstrates clearly that the effect of the 'flotation agents" is nonexistent in preventing adhesion formation both in laparotomy and in laparoscopy (50,51).

This is due to the rapid absorption of the liquids by the peritoneum at a rate of 30-60 ml/h leading to the disappearance of the fluids within 24-48 h. This time span is too short to be effective in preventing adhesion formation.

ISGE recommendation flotation barriers should not be used to prevent adhesion formation. Grade II-1: D

Adept (4% icodextrin solution – Baxter Biosurgery, Baxter International, Deerfield II, USA) used in animal and peritoneal dialysis seems to have sufficient long intra peritoneal

presence to prevent adhesion formation (52). Standard recommendation is to use the solution throughout the surgery and leave 1.000 ml in the abdomen at termination of the surgery (53,54). One randomized controlled pilot study where lavage during surgery and instillation of 4% icodextrin was practiced showed the treatment to be well tolerated and above all did show a reduced incidence in adhesion formation both in extent and severity at laparoscopic adnexal surgery however the group sizes were not powered to statistical significance (54). More recently these findings have been confirmed in a study concerning patients operated for adhesions (55). As adverse reactions are listed: vulvar edema, allergic reactions (allergy to starch based polymers and iso-maltose intolerance), fluid leakage through the wounds and in some cases abdominal distention and discomfort (56).

ISGE recommendation: 4% icodextrin solution can be used, in the prescribed methodology, in patients operated for ADR. Grade I: C.

2. Gel barriers

#### Hyaluronic Acid

In a large multicenter randomized trial Intergel<sup>®</sup> (ferric hyaluronate, Ethicon – J&J, Somerville, New Jersey, USA) was proved to be effective in reducing the extension and severity of postoperative adhesions as compared to Ringer's solution in patients undergoing peritoneal cavity surgery by laparotomy with a planned secondlook laparoscopy (57).

Due to unacceptable post-operative complications the gel is no longer available (58).

Hyalobarrier Gel Endo (Auto-cross linked hyaluronic acid, Nordic Pharma, Dublin Ireland) is suitable for use to prevent adhesion formation in abdominal surgery due to its adhesivity and

prolonged stay in time on the treated surfaces. Thirty-six patients, treated with Hyaolobarrier Gel Endo in a randomized controlled study, who underwent laparoscopic myomectomy showed a significant reduction in postoperative adhesion formation (59). The same authors did demonstrate the application of the gel in cases of laparoscopic myomectomy to be associated with an increased pregnancy rate (60). These findings including a favorable safety profile have been confirmed in a blinded, randomized, multicenter study provided the gel is used at the end of the

ISGE recommendation there is sufficient evidence to recommend the use of Hyalobarrier gel after laparoscopic surgery for myomata. Grade I: A

surgery as rinsing is able to remove the gel (61).

Solution of hyaluronic acid, Sepracoat<sup>®</sup> coating solution, a solution of hyaluronic acid, (HAL-C; Genzyme Corporation, Cambridge, USA), is a liquid composed of 0.4 % sodium hyaluronate in phosphate buffered saline, it is applied intraoperative, prior to the dissection, to protect peritoneal surfaces from indirect surgical trauma or post-operatively to separate surfaces after they are traumatized. There are no studies in the literature evaluating Sepracoat<sup>®</sup> in preventing adhesions following laparoscopic gynecological procedures. The efficacy in laparotomy was well established (62).

ISGE recommendation there is enough evidence to recommend Sepracoat<sup>2</sup> in open surgery. Grade I: A

Hydrogel, Spraygel<sup>®</sup> or Sprayshield<sup>®</sup> (Covidien, Dublin, Ireland) consist of two synthetic liquid precursors that, when mixed, rapidly cross-link to form a solid, flexible, absorbable hydrogel. The

solid polymer is easily applied by laparoscopy; however, it can only be applied when in contact with room air after evacuation of the CO2 this could cause air-embolisms. Sprayshield<sup>®</sup> sprayed over the affected area and remains for approximately 5 to 7 days. There after it is degraded and absorbed. One of the components contains a blue food colorant, so there is an intraoperative visualization where the gel is used. The currently available evidence does not support the use of Sprayshield<sup>®</sup> either decreasing the extent of adhesion or in reducing the proportion of women with adhesions. In a prospective blinded observational study our group, Bruno Johan van Herendael, Benedikt Tas, Marc Francx and Bart De Vree at Ziekenhuis Netwerk Antwerp, 2004 -2005 evaluated 22 patients treated with Sprayshield with second look laparoscopy compared to 22 non treated, comparable patients. The conclusion was that using the gel did reduce de novo adhesions at second look laparoscopy as compared to the non-treated patients but the study is too small to draw conclusions (Randomised observational prospective trial: never published) (Fig 5). Mettler et al randomized 64 women undergoing a myomectomy by laparoscopy or laparotomy. Only 22 returned for a second look laparoscopy. Although the treated patients were more adhesion free at second look laparoscopy compared with the control group; the difference was not significant (63). More randomized and especially blinded prospective studies are need to obtain scientific proof of the efficacy of Sprayshield<sup>®</sup>

## Other gel barriers

Intercoat<sup>®</sup> (Ethicon – J&J, Somerville, New Jersey, USA) a viscoelastic absorbable gel of polyethylene oxide and carbomethylcellulose is stabilized by calcium chloride. At the end of the

11

procedure the coating is applied in a single layer to function as a mechanical barrier. Lundorff et al published the results of a randomized third party blinded multicenter European trial showing that visco-elastic gel did significantly reduce adnexal adhesions in patients undergoing gynecological laparoscopic surgery (64).

At the same time period Young et al published a randomized study evaluating Oxiplex/AP<sup>2</sup> gel (FzioMed, San Luis Obospo, California) Their conclusion is that the gel is safe, easy to use during laparoscopic surgery and contributes to a reduction of adnexal adhesions (65).

CoSeal (resorbable hydrogel polyethylene glycolpolymer solution - Baxter Biosurgery, Deerfield, II USA) is extensively used in vascular surgery reconstruction operations (over 200.00 patients since 2002). In both open and laparoscopic surgery, provided good surgical technique is used, the gel reduces significantly, incidence, extent and severity of postoperative adhesions (66).

ISGE recommendation: There is evidence that both other gel barriers are safe to use and do reduce adhesion formation. Grade II-2: A

### 3. Sheets

Gore-Tex Surgical membrane (W.L. Gore & Associates Inc, Flagstaff, USA) The expanded polytetrafluorethylene non absorbable barrier is characterized by a microscopic structure preventing cellular ingrowth at the same time it is non-inflammatory. In patients undergoing laparotomy for adhesiolysis or myomectomy the membrane decreases the severity, extent and incidence of adhesions (67). The limitations of the membrane are that it has to be sutured in place and removed during subsequent surgery. It Corresponding author: Bruno J van Herendael bruno.vanherendael@isge.org

is therefore very difficult to use it at laparoscopic surgery.

Interceed (Ethicon–J&J, Sommerville, New Jersey, USA) The oxidized regenerated cellulose membrane is widely used to prevent adhesions at surgery as it has been proved to reduce adhesion formation in animals and in human. The damaged peritoneal surfaces are covered with the membrane that transforms itself to a gelatinous mass. In doing so it forms a physical barrier that separates adjacent damaged peritoneal surfaces. Over 13 clinical trials including 600 patients have been performed. The meta-analysis of 10 randomized control trials reported 24.2% reduced adhesion formation on the side treated with the barrier (68). However, in the presence of bleeding the sheet seems to aggravate adhesion formation rather than reduce it.

Seprafilm (Genzyme Biosurgery, Bridgewater, USA) this sodium hyaluronate carbomethylcellulose membrane ids placed over a suture or an injured peritoneum without stich and remains there for some seven days. Here a bleeding seems not to impair the efficacy of membrane. In general surgery several studies did report the efficacy of Seprafilm<sup>®</sup> over 20 studies on over 4000 patients are reported in the literature (67). The problem in laparoscopy is that the membrane is fragile and difficult in use.

### 4. Drugs

The NSAID ketorolac has shown some evidence prevent adhesions in animals (69). to Dexamethasone combined with noxythiolin (peritoneum antiinfection agent) have been tested in 126 patients operated by microsurgery and assessed by a second look laparoscopy three to six months later. In the control group 19% of the patients became pregnant versus 40% of patients in the treated group (p<0.02). The improvement in the adhesion score in the treated group was 23.3 and in the control group 10.2 (70).




Fig 5: Second Look laparoscopy: White arrow subtle thin adhesions after major posterior myomectomy after the use of barriers (Sprayshield<sup>D</sup>). Blue arrows: impressions of the ischemic sutures at laparoscopic myomectomy using Vicryl 1 resorbable suture. (ZNA series second look)

### Discussion

The general consensus is that adhesion formation is a persistent companion in surgery sometimes leading to ARD. To reduce ARD to a minimum good surgical technique is the key ingredient to maximal reduction of postoperative adhesion formation. It is important to adhere to Evidence Based Medicine (EBM). EBM being the integration of individual clinical expertise, best available external clinical evidence and last but not least patient's values and expectations. Individual clinical expertise boils down to good surgical technique and the fact that it could be better to consult a colleague with expertise in ARD and send the patient to his/her center eventually to go and assist the colleague to get personal expertise. In ARD due to postoperative adhesion formation, it is important to adhere to the second pilar of EBM and integrate the best available external clinical evidence in our judgement as to help the individual patient the best possible way at the least costs for the health system. Although EBM is never sufficient to make clinical decision, EBM points to a hierarchy of evidence so that the individual surgeon can make her/his specific clinical decision. The patient's values and expectations can be multiple but in essence these will be functional solutions to the patient's problem be it infertility or abdominal discomfort and pain. This does not mean an anatomical solution but rather a functional solution to the problems at hand.

In hysteroscopic surgery the data suggest that mechanical tools, scissors and morcellation, interfere the least with the endometrium. In the prevention of IUA only an in office second look hysteroscopy after 6 weeks in the immediate postmenstrual period is congruent with the above EBM principles. Postoperative hyaluronic gel application can be of help but is quite expensive and at this moment in time there is no evidence. Estrogen in whatever dosage can be given especially in patients with proven hypotrophic endometrium at biopsy. There is no proof of its efficacy in hormonal balanced premenopausal patients.

Concerning open surgery, laparoscopic surgery and gasless laparoscopic surgery meticulous surgical technique is of utmost importance. Residual blood should be avoided and this can be obtained by careful hemostasis and rinsing with Ringers Lactate with heparin. The proper sutures should be used and preferable no braided sutures are left in the abdominal cavity. The use of floatation barriers does not seem to add substantial benefit in the prevention of

adhesions. Gel barriers (Hyalobarrier gel Endo<sup>®</sup> or Intercoat<sup>®</sup>) based on hyaluronic acid are proven to have a significant effect on adhesion prevention. The inconvenient is that these gel barriers are costly. We therefore do advocate a very cautious and proper use of these barriers. As for sheets there is enough evidence, they prevent adhesions. The use of NSAID in the prevention of pain and or corticosteroids in the prevention of post-operative nausea is already mainstay after surgery and can be further endorsed in the prevention of adhesions. A resume of the above reflection can be found in table 2.

Altering the laparoscopic gas to a mixture of carbon dioxide + 10% nitrous oxide + 4% oxygen may be a future option as this is an easy way to prevent adhesions, but further studies are needed to provide stronger data regarding efficacy and safety.

# **ISGE Recommendations**

Prevention of adhesions post operative			LOE
Hysteroscopy	IUCD	No evidence	I: A
		No evidence	
	Barriers	better pregnancy	I: A
		rates	
		Evidence	
		less adhesion	I: C
		formation	
	Oestrogens	No evidence	II-1: C
	Steroids	No evidence	II-2: C
Laparoscopy	Blood	Evidence	II-2: A

Sutures and meshes	Evidence	II-1: B
Flotation barriers	No evidence	II-1:D
Adept®	Evidence	I: C
Intergel®	Evidence	I: E
Hyalobarrie r gel®	Evidence	I: A
Sepracoat ®	Evidence	I: A
Sprayshiel d®	No Evidence	II-2: C
Intercoat ® Oxiplex/A P®	Evidence	II-2: A
CoSeal®	Evidence	II-1: A
Gore-Tex	Evidence	II-2: A
Interceed ®	Evidence	I: C
Seprafilm ®	Evidence	II-2: B

Tab 3: ISGE recommendations to prevent adhesions in hysteroscopy and laparoscopy, open surgery and gasless laparoscopy.

GRADE approach - grading of recommendations, risk/benefit and quality of supporting evidence.

Grade of recommendation	Risk/benefit	Quality of supporting evidence
<b>1A.</b> Strong recommendation, high quality evidence	Benefits clearly outweigh risk and burdens, or vice versa.	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.
<b>1B.</b> Strong recommendation, moderate quality evidence	Benefits clearly outweigh risk and burdens, or vice versa.	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.
1C. Strong recommendation, low quality evidence	Benefits appear to outweigh risk and burdens, or vice versa.	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.
<b>2A.</b> Weak recommendation, high quality evidence	Benefits closely balanced with risks and burdens.	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.
<b>2B.</b> Weak recommendation, moderate quality evidence	Benefits closely balanced with risks and burdens, some uncertainly in the estimates of benefits, risks and burdens.	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.
<b>2C.</b> Weak recommendation, low quality evidence	Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens.	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.

Tab 4 Recommendations Different grades and their explanation.

# References

1. Ellis D. Moran BJ, Thompson JN et al: Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. The Lancet 1999 May; 1:353.

2. Liakakos T, Thomakos N, Fine PM, Dervenis C, Young RL (2001) Peritoneal adhesions: etiology, pathophysiology, and clinical significance recent advances in prevention and management. Dig Surg 18:260–273.

3. Lower AM, Hawthorn RJ, Ellis H, O'Brien F, Buchan S, Crowe AM. The impact of adhesions on hospital readmissions over ten years after 8849 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study. BJOG 2000; 107:855-62.

4. Taskin O, Sadik S, Onoglu A, Gokdeniz R, Erturan E, Burak F, Wheeler JM Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):351-4.

5. Asherman JG Traumatic intrauterine adhesions. Br J Obstet Gyneacol 1950; 57:892-896.

6. Yang JH, Chen MJ, Chen CD, Chen SU, Ho HN, Yang YS. Optimal waiting period for subsequent fertility treatment after various hysteroscopic surgeries. Fertil Steril. 2013 Jun;99(7):2092-6. e3.

7. Menzies D, Ellis H. Intestinal obstruction from adhesions--how big is the problem? Ann R Coll Surg Engl. 1990;72:60-63.

8.Van der Krabben AA, Dijkstra FR, Nieuwenhuijzen M, Reijnen MMPJ, Schaapveld M, van Goor H. Morbidity and mortality of inadvertent enterotomy during adhesiotomy. Br J Surg 2000;87:467-71.

9. Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertil Steril. 1982; 37:593–61.

10. Kodaman PH, Arici A. Intra-uterine adhesions and fertility outcome: how to optimize success? Curr Opin Obstet Gynecol. 2007;19(3):207–214.

11. Deans R, Abbott J. Review of intrauterine adhesions. J Minim Invasive Gynecol. 2010; 17:555.

12. Nappi C, Di Spiezio Sardo A, Greco E, Guida M, Bettocchi S, Bifulco G. Prevention of adhesions in gynaecological endoscopy. Hum Reprod Update. 2007 Jul-Aug;13(4):379-94.

13. Revaux A, Ducarme G, Luton D. Prevention of intrauterine adhesions after hysteroscopic surgery. Gynecol Obstet Fertil. 2008 Mar;36(3):311-7.

14. diZerega GS. Biochemical events in peritoneal tissue repair. Eur.J. Surg.Suppl 1997;10-16.

15. diZerega GS, Campeau JD. Peritoneal repair and post-surgical adhesion formation. Hum Reprod Update. 2001; 7:547-55.

16. Verguts J, Bosteels J, Corona R, Hamerlynck T, Mestdagh G, Nisolle M, Puttemans P, Squiflet JL, van Herendael BJ, Weyers S. Belgian Consensus on Adhesion Prevention in Hysteroscopy and laparoscopy. Gynecol Surg 2015 DOI 10.1007/s10397-015-0887-3

17. Fotev Z, Whitaker D, Papadimitriou JM. Role of Macrophages in Mesothelial Healing. J Pathol 1987; 151:209-19.

18. Tolhurst Cleaver CL, Hopkins AD, Kee Kwong KC, Raftery AT. The effect of postoperative peritoneal lavage on survival, peritoneal wound healing and adhesion formation following fecal peritonitis: an experimental study in the rat. Br J Surg 1974; 61:601-04.

19. Corona R, Verguts J, Schonman R, Binda MM, Mailova K, Koninckx PR. Postoperative inflammation in the abdominal cavity increases adhesion formation in a laparoscopic mouse model. Fertil Steril. 2011 Mar 15;95(4):1224-8.

20. Molinas CR, Tjwa M, Vanacker B, Binda MM, Elkelani O, Koninckx PR. Role of CO<sub>2</sub> pneumoperitoneum-induced acidosis in CO<sub>2</sub> pneumoperitoneum-enhanced adhesion formation in mice. Fertil Steril. 2004 Mar;81(3):708-11.

21. Corona R, Verguts J, Koninckx R, Mailova K, Binda MM, Koninckx PR. Intraperitoneal temperature and desiccation during endoscopic surgery. Intraoperative humidification and cooling of the peritoneal cavity can reduce adhesions. Am J Obstet Gynecol. 2011 Oct;205(4): 392.e1-7.

22. Bentes de Souza AM, Chiu Wang C, Yan Chu C, Lam PM, Scott Rogers M. The effect of intraabdominal pressure on the generation of 8-iso prostaglandin F2alpha during laparoscopy in rabbits. Hum Reprod 2003 Oct;18(10):181-8. Doi.10.1093/humrep/deg405.

23. March CM, Israel R. Gestational outcome following hysteroscopic lysis of adhesions. Fertil Steril. 1981 Oct;36(4):455-9.

24. Vesce F, Jorizzo G, Bianciotto A, Gotti G. Use of the copper intrauterine device in the management of secondary amenorrhea. Fertil Steril. 2000 Jan;73(1):162-5.

25. Orhue AA, Aziken ME, Igbefoh JO. A comparison of two adjunctive treatments for intrauterine adhesions following lysis. Int J Gynaecol Obstet. 2003 Jul;82(1):49-56.

26. Deans R, Abbott J. Review of intrauterine adhesions. J Minim Invasive Gynecol. 2010 Sep-Oct;17(5):555-69.

27. Sanfilippo JS, Fitzgerald MR, Badawy SZ, Nussbaum ML, Yussman MA. Asherman's syndrome. A comparison of therapeutic methods. J Reprod Med. 1982 Jun;27(6):328-30.

28. Acunzo G, Guida M, Pellicano M, Tommaselli GA, Di Spiezio Sardo A, Bifulco G, Cirillo D, Taylor A, Nappi C. Effectiveness of auto-cross-linked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic adhesiolysis: a prospective, randomized, controlled study. Hum Reprod. 2003;18(9):1918–1921

29. De Iaco PA, Muzzupapa G, Bovicelli A, Marconi S, Bitti SR, Sansovini M, Bovicelli L. Hyaluronan derivative gel (Hyalobarrier gel) in intrauterine adhesion (IUA) prevention after operative hysteroscopy. Ellipse. 2003;19(1):15–18.

30. Di Spiezio Sardo A, Spinelli M, Bramante S, Scognamiglio M, Greco E, Guida M, Cela V, Nappi C. Efficacy of a polyethylene oxide—sodium carboxymethylcellulose gel in prevention of Corresponding author: Bruno J van Herendael bruno.vanherendael@isge.org DOI: 10.36205/trocar trocar3.2022001 Received 08.2022 - Accepted 09.2022 intrauterine adhesions after hysteroscopic surgery. J Minim Invasive Gynecol. 2011;18(4):462–469.

31. Guida M, Acunzo G, Di Spiezio Sardo A, Bifulco G, Piccoli R, Pellicano M, Cerrota G, Cirillo D, Nappi C. Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Hum Reprod. 2004;19(6):1461–1464.

32. Pansky M, Fuchs N, Ben Ami I, Tovbin Y, Halperin R, Vaknin Z, Smorgick N. Intercoat (Oxiplex/AP Gel) for preventing intrauterine adhesions following operative hysteroscopy for suspected retained products of conception—a pilot study. J Minim Invasive Gynecol. 2011;18(S21):68

33. Bosteels J, Weyers S., Mol B, D'Hooghe T. Anti-adhesion barrier gels following operative hysteroscopy for treating female subfertility: a systematic review and meta-analysis. Gynecological Surgery 2014; 11: 113-127.

34. Wood J, Pena G. Treatment of traumatic uterine synechia's. Int J Fertil. 1964 Apr-Jun; 9:405-10.

35. Magos A. Hysteroscopic treatment of Asherman's syndrome. Reprod Biomed Online. 2002;4 Suppl 3:46-51. Review.

36. Watson A, Vandekerckhove P, Lilford R. Liquid and fluid agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev. 2000;(3):CD001298.

37. Metwally M, Watson A, Lilford R, Vandekerckhove P. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001298.

38. Haimovich S, Mancebo G, Alameda F, Agramunt S, Solé-Sedeno JM, Hernández JL, Carreras R. Feasibility of a new two-step procedure for office hysteroscopic resection of submucous myomas: results of a pilot study. Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):191-4.

39. van Wessel S, van Vliet H AAM, Schoot BC, Weyers S, Hamerlynck TWO. Hysteroscopic morcellation versus bipolar resection for removal of type 0 and 1 submucous myomas: A randomized trial Eur J Obstet Gynecol Reprod Biol. 2021 Apr; 259:32-37. doi: 10.1016/j.ejogrb.2021.01.050. Epub 2021 Jan 29.

40. Hamerlynck TW, van Vliet HA, Beerens AS, Weyers S, Schoot BC. Hysteroscopic Morcellation versus Loop Resection for Removal of Placental Remnants: a Randomized trial. J Minim Invasive Gynecol. 2016 Nov-Dec;23(7):1172-1180. doi: 10.1016/j.jmig.2016.08.828. Epub 2016 Aug 30.

41. Risberg B. Adhesions: preventive strategies. Eur J Surg Suppl. 1997;(577):32-9.

42. Robertson D, Lefebvre G, Leyland N, Wolfman W, Allaire C, Awadalla A, Best C, Contestabile E, Dunn S, Heywood M, Leroux N, Potestio F, Rittenberg D, Senikas V, Soucy R, Singh S; Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines: Adhesion prevention in gynaecological surgery: no. 243, June 2010. Int J Gynaecol Obstet. 2010 Nov;111(2):193-7.

43. Rock JA, Thompson JD in Te Linde's Operative Gynecology Rock JA and Thompson JD editors Lippincott – Raven Philadelphia PA 1977 Chapter 11 p 214)

44. Corona R, Binda MM, Mailova K, Verguts J, Koninckx PR. Addition of nitrous oxide to the carbon dioxide pneumoperitoneum strongly decreases adhesion formation and the dose-dependent adhesiogenic effect of blood in a laparoscopic mouse model. Fertil Steril. 2013 Dec;100(6):1777-83.

45. Diamond MP, Decherney AH. Pathogenesis of adhesion formation/reformation: application to reproductive pelvic surgery. Microsurgery. 1987;8(2):103-7. Review.

46. Wang I, Maejima T, Nishihara S, Yoshikawa, Kono T. Bowel obstruction and perforation secondary to barbed suture after minimally invasive inguinal hernia repair: a report of two cases and literature review. Surg Case Rep 2021;7(1):161 DOI 10.1186/s40792-02149-w.

47. Luijendijk RW, de Lange DC, Wauters CC, Hop WC, Duron JJ, Pailler JL, Camprodon BR, Holmdahl L, van Geldorp HJ, Jeekel J. Foreign material in postoperative adhesions. Ann Surg. 1996 Mar;223(3):242-8.

48. Koninckx PR, Corona R, Timmerman D, Verguts J, Adamyan L. Peritoneal full-conditioning reduces postoperative adhesions and pain: a randomised controlled trial in deep endometriosis surgery. J Ovarian Res. 2013 Dec 11;6(1):90.

49. Mynbaev OA, Biro P, Eliseeva MY, Tinelli A, Malvasi A, Kosmas IP, Medvediev MV, Babenko TI, Mazitova MI, Simakov SS, Stark M. A: Koninckx PR, Corona R, Timmerman D, Verguts J, Adamyan L. Peritoneal full-conditioning reduces postoperative adhesions and pain: a randomised controlled trial in deep endometriosis surgery. J Ovarian Res. 2013 Dec 11;6(1):90. J Ovarian Res. 2014 Mar 10;7(1):29.

50. Wiseman DM, Trout JR, Diamond MP. The rates of adhesion development and the effects of crystalloid solutions on adhesion development in pelvic surgery. Fertil Steril. 1998 Oct;70(4).

51. Ahmad G, Mackie FL, Iles DA, O'Flynn H, Dias S, Metwally M, Watson A. Fluid and pharmacological agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev. 2014 Jul 9;7:CD001298.

52. Harris ES, Morgan RF, Rodehaver GT. Analysis of the kinetics of peritoneal adhesion formation in the rat an evaluation of potential antiadhesive agents. Surgery 1995; 117:663-669.

53. Verco SJS, Peers EM, Brown CB, Rodgers KE, Roda N, diZerega GS. Development of a novel glucose polymer solution (icodextrin) for adhesion prevention: pre-clinical studies. Hum Reprod 2000;15:1764-1772

54. diZerega GS, Verca SJS, Young P, Kettel M, Kobak W et al. A randomized, controlled pilot study of the safety and efficacy of 4% icodextrin solution in the reduction of adhesions following laparoscopic gynecological surgery. Human Reprod 2002; 17:1031-1038.

55. Brown CB, Luciano AA, Martin D, Peers E, Scrimgeour A, diZerega GS. On behalf of the Adept Adhesion Reduction Study Group. Adept<sup>®</sup> (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study. Fertil Steril 2006; 88:1413-1426.

56. Douplis D, Majeed GS, Sieunarine K, Richardson R, Smith JR. Adverse effects related to icodextrin 4%. Our experience. Gynaecol Surg 2007; 4:97-100.

57. Johns DB, Keyport GM, Hoehler F, diZerega GS; Intergel Adhesion Prevention Study Group Reduction of postsurgical adhesions with Intergel adhesion prevention solution: a multicenter study of safety and efficacy after conservative gynecologic surgery. Fertil Steril. 2001 Sep;76(3):595-604.

58. Tang CL, Jayne DG, Seow-Choen F, Ng YY, Eu KW, Mustapha N. A randomized controlled trial of 0.5% ferric hyaluronate gel (Intergel) in the prevention of adhesions following abdominal surgery. Ann Surg. 2006 Apr;243(4):449-55.

59. Pellicano M, Bramante S, Cirillo D, Palomba S, Bifulco G, Zullo F, Nappi C. Effectiveness of autocross linked hyaluronic acid gel after laparoscopic myomectomy in infertile patients: a prospective, randomized, controlled study. Fertil Steril. 2003 Aug;80(2):441-4.

60. Pellicano M, Guida M, Bramante S, Acunzo G, Di Spiezio Sardo A, Tommaselli GA, Nappi C. Reproductive outcome after autocross linked hyaluronic acid gel application in infertile patients who underwent laparoscopic myomectomy. Fertil Steril. 2005 Feb;83(2):498-500.

61. Mais V, Bracco GL, Litta P, Gargiulo T, Melis GB. Reduction of postoperative adhesions with an auto-crosslinked hyaluronan gel in gynaecological laparoscopic surgery: a blinded, controlled, randomized, multicenter study. Hum Reprod. 2006 May;21(5):1248-54.

62. Diamond MP. Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. The Sepracoat Adhesion Study Group. Fertil Steril. 1998 Jun;69(6):1067-74.

63. Mettler L, Audebert A, Lehmann-Willenbrock E, Schive-Peterhansl K, Jacobs VR. A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy. Fertil Steril. 2004 Aug;82(2):398-404.

64. Lundorff P, Donnez J, Korell M, Audebert AJM, Block K, diZerega GS. Clinical evaluation of a viscoelastic gel for reduction of adhesions following gynaecological surgery by laparoscopy in Europe. Hum Reprod 2005; 20:514-520.

65. Young P, Johns A, Templeman C, Witz C, Webster B, Ferland R, Diamond MP, Block K, diZerega G. Reduction of postoperative adhesions after laparoscopic gynecological surgery with Oxiplex/AP Gel: a pilot study. Fertil Steril. 2005 Nov;84(5):1450-6.

66. Mettler L, Hucke J, Bojar B, Tinneberg HR, Leyland N, Avelar A. A safety and efficacy study of the resorbable hydrogel for reduction of post-operative adhesions following myomectomy. Human Reprod 2008; 23:1093-100.

67. Farquhar C, Vandekerckhove P, Watson A, Vail A, Wiseman D. Barrier agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev. 2000;(2):CD000475.

68. Wiseman DM, Trout JR, Franklin RR, Diamond MP. Metanalysis of the safety and efficacy of an adhesion barrier (Interceed TC7) in laparotomy. J Reprod Med. 1999 Apr;44(4):325-3.

69. Montz FJ, Monk BJ, Lacy SM, Fowler JM. Ketorolac tromethamine, a nonsteroidal antiinflammatory drug: ability to inhibit post-radical pelvic surgery adhesions in a porcine model. Gynecol Oncol. 1993 Jan;48(1):76-9.

70. Querleu D, Vankeerberghen-Deffense F, Boutteville C. Adjuvant treatment of tubal surgery. Randomized prospective study of systemically administered corticoids and noxythiolin. J Gynecol Obstet Biol Reprod (Paris). 1989;18(7):935-40.